Business Context and Reporting Period
Company: Supernus Pharmaceuticals, Inc. (SUPN)
Filing Type: Form 8-K (Current Report)
Date of Report: February 4, 2025
Principal Event: Receipt of final U.S. Food and Drug Administration (FDA) approval for SPN-830 (ONAPGO).
Key Financial Metrics
This filing is a Current Report (Form 8-K) regarding a regulatory milestone and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material change reported is the regulatory approval of ONAPGO for the continuous treatment of motor fluctuations (OFF episodes) in people with Parkinson's disease (PD) who are not adequately controlled with oral levodopa and one or more adjunct PD medications.
Guidance, Outlook, and Risks
Management Commentary: The Company issued a press release (Exhibit 99.1) announcing the FDA approval. No specific financial guidance, outlook, or risk factors are detailed within the body of this 8-K filing.
Investor Verification Checklist
- Verify the commercial launch timeline for ONAPGO following FDA approval.
- Review the full text of the press release (Exhibit 99.1) for details on market access and pricing strategy.
- Assess the potential revenue impact of ONAPGO on the Company's upcoming quarterly and annual financial reports.
- Monitor for any subsequent filings regarding the commercialization plan or partnership agreements related to this product.